Huppert Discusses Later-Line Therapy Decisions in HR+, HER2– Metastatic Breast Cancer
October 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Laura Huppert, MD, and participants discussed treatment approaches for a patient HR-positive, HER2-negative breast cancer with liver and lung metastases who continues to progress on endocrine therapy and CDK4/6 inhibitors.
Arend Discusses Immune Checkpoint Inhibition for Recurrent dMMR Endometrial Cancer
October 17th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Rebecca Arend, MD, and participants discussed the use of single-agent immune checkpoint inhibitor as opposed to pembrolizumab plus lenvatinib in a patient with recurrent mismatch-repair deficient endometrial cancer.
Discussing Rationale for Combination Therapy in Metastatic Melanoma
October 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Hussein A. Tawbi, MD, PhD, and participants discussed which first-line therapy they would recommend for a 78-year-old patient with metastatic melanoma and no BRAF-activating mutation. This is the first of 2 articles based on this event.
Immunotherapy Plus TKI Yields Impressive Results for Subgroups With Advanced RCC
October 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel George, MD, discussed the CheckMate 9ER trial in terms of bone, liver, and lung metastases and other subgroups in patients with advanced clear cell renal cell carcinoma.
Randall Reviews Efficacy and Safety of Niraparib as Primary Maintenance for Ovarian Cancer
October 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Leslie M. Randall, MD, MAS, evaluated the outcomes of the PRIMA/ENGOT-OV26/GOG-3012 study of niraparib as primary maintenance therapy for patients with ovarian cancer.
Targeting BCMA With Teclistamab Produces Impactful Results in RRMM
October 12th 2023In the first article of a 2-part series, Sikander Ailawadhi, MD, looks at how the field has changed for treatment of patients with relapsed/refractory multiple myeloma and how recent study results with teclistamab show the impact of targeting BCMA in these patients.
Physicians Discuss Treatment Preference in R/R B-Cell Precursor ALL
October 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Nicholas Short, MD, and participants discussed which patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia they would treat with inotuzumab ozogamicin.
Lunning Discusses Defining and Approaching Treatment for Early-Relapsed DLBCL
October 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew A. Lunning, DO, and participants discussed how they approach treatment for a patient with diffuse large B-cell lymphoma who relapsed 8 months after primary therapy.
Physicians Discuss Elacestrant Vs Alternatives in ER+, HER2- MBC
October 9th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, discussed with other physicians their experience with elacestrant in patients with estrogen receptor–positive, HER2-negative breast cancer. This is the second article based on this event.
Single-Agent Talquetamab Stands Out in Later-Line Treatment of RRMM
October 5th 2023In the second article of a 2-part series, Amrita Krishnan, MD, looks at the overall landscape of treatment for patients with relapsed/refractory multiple myeloma and how the use of single-agent talquetamab stands out in comparison with other treatment options.
Randomized Trial Provides Biomarker and CNS Sotorasib Data in NSCLC
October 4th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the results of the phase 3 CodeBreaK 200 trial in patients with KRAS G12C-positive lung cancer. This is the second article based on this event.
Supportive Care Methods in Later Lines of Therapy in RRMM
October 3rd 2023In the second article of a 2-part series, Jack Khouri, MD, discusses with a group of physicians what supportive care options, such as anti-nausea medicine and dose modifications, are important when treating a patient with relapsed/refractory in the third-line setting and beyond.
Bispecific T-Cell Engagers Emerge as Later-Line Therapies for DLBCL
October 2nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Medhi H. Hamadani, MD, discussed the bispecific T-cell engagers epcoritamab and glofitamab and how they fit into the treatment algorithm for patients with diffuse large B-cell lymphoma. This is the second of 2 articles based on this event.
Physicians Discuss Modifying Use of CDK4/6 Inhibitors in ER+/HR+ Metastatic Breast Cancer
September 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, and participants discussed switching CDK4/6 inhibitors and continuing use beyond progression in patients with metastatic breast cancer. This is the first of 2 articles based on this event.
Debating When to Switch TKIs and How to Ensure Patient Adherence in CML
September 28th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Kendra Sweet, MD, and participants discussed dosing and toxicity concerns with tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia.
Bryce Reviews PARP Inhibitor Combination Trials in Prostate Cancer
September 27th 2023During a Targeted Oncology™ Community Case Forum event in partnership with The Arizona Clinical Oncology Society, Alan H. Bryce, MD, reviewed data from clinical trials utilizing PARP inhibitors in patients with prostate cancer.
Identifying the Role of Targeted Therapy in KRAS-Mutated NSCLC
September 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the use of sotorasib and adagrasib for patients with KRAS-mutated non–small cell lung cancer including those with brain metastases.
Atkins Assesses the Differences Between Immunotherapy Strategies in Advanced Melanoma
September 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed with participants what factors influence the choice of first-line immunotherapy for a patient with BRAF–wild-type metastatic melanoma.
Pemmaraju Discusses Development of Targeted Therapy for BPDCN
September 25th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, explained the research he and others conducted leading to the development of tagraxofusp-erzs to treat patients with blastic plasmacytoid dendritic cell neoplasm.
Salani Reviews Options for a Patient With Metastatic Endometrial Cancer
September 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Ritu Salani, MD, MBA, discussed trials supporting the use of the immune checkpoint inhibitors pembrolizumab and dostarlimab in patients with metastatic endometrial cancer.